TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20934685

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting-list condition (n=17)
Number of subjects: 34
Study: 19038389

Group type: EXPERIMENTAL
Intervention: Staccato reperfusion (SR)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Abrupt reperfusion (AR)
Number of subjects: 37
Study: 17005527

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cinacalcet withdrawal
Number of subjects: 12
Study: 15764014

Group type: EXPERIMENTAL
Intervention: Stressor before retrieval
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stressor before learning
Number of subjects: 60

Group type: COMPARATOR
Intervention: No stress
Number of subjects: 60
Study: 11369156

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg intravenous infusion over one hour)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline solution intravenous infusion over one hour)
Number of subjects: 12
Study: 8988992

Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia (5 mg.kg‐1.h‐1 prior to sternotomy, 3 mg.kg‐1.h‐1 thereafter)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Enflurane-based anesthesia (0.2%-1.0%)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 8213569

Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA)
Number of subjects: 100
Study: 2956957

Group type: EXPERIMENTAL
Intervention: cilostazol (CS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ticlopidine (TP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA)
Number of subjects: 9
Study: 30950283

Group type: EXPERIMENTAL
Intervention: Evening Training (EG)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Morning Training (MG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 52
Study: 28731562

Group type: EXPERIMENTAL
Intervention: Telephone-based behavioural weight loss intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study: 25365133

Group type: EXPERIMENTAL
Intervention: HIP protocol
Number of subjects: 199

Group type: COMPARATOR
Intervention: KNEE protocol
Number of subjects: 199
Study: 22766268

Group type: EXPERIMENTAL
Intervention: recombinant human bone morphogenetic protein‐7 (rhBMP‐7) with deproteinised bone substitute (0.5 g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: deproteinised bone alone (2.0 g)
Number of subjects: 9
Study: 20147570

Group type: EXPERIMENTAL
Intervention: 10 µg dDAVP combined with 10 µg hCRH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 µg dDAVP combined with 30 µg hCRH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 µg dDAVP alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 µg hCRH administered two hours after 10 µg dDAVP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 µg dDAVP followed by 100 µg hCRH
Number of subjects: 12
Study: 19190453

Group type: EXPERIMENTAL
Intervention: Asymptomatic cortical venous drainage (aCVD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Symptomatic cortical venous drainage (sCVD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Overall comparison of aCVD vs sCVD
Number of subjects: 28
Study: 17126653

Group type: EXPERIMENTAL
Intervention: Usual care plus team case management
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study: 15501836

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600,000 i.u. ergocalciferol)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 11171729

Group type: EXPERIMENTAL
Intervention: IV combination of diltiazem and digoxin
Number of subjects: 52

Group type: COMPARATOR
Intervention: IV diltiazem alone
Number of subjects: 52
Study: 9603556

Group type: EXPERIMENTAL
Intervention: Presurgical orthopedic treatment (PSOT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-presurgical orthopedic treatment (non-PSOT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PSOT
Number of subjects: 52

Group type: COMPARATOR
Intervention: non-PSOT
Number of subjects: 52
Study: 7997340

Group type: EXPERIMENTAL
Intervention: Hip Guidance Orthosis (HGO)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reciprocating Gait Orthosis (RGO)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Advanced Reciprocating Gait Orthosis (ARGO)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall use of orthoses
Number of subjects: 28
Study: 3276384

Group type: EXPERIMENTAL
Intervention: Regional hyperthermic cytostatic perfusion with melphalan (42 degrees C)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (wide excision and lymph node dissection)
Number of subjects: 107
Study: 30348455

Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension (KTT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Kinesio Taping no tension (KTNT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 108
Study: 28492456

Group type: EXPERIMENTAL
Intervention: Calmer Life (CL) intervention, a community-based, person-centered, flexible and culturally tailored intervention for late-life anxiety and worry.
Number of subjects: 0
Study: 26478577

Group type: EXPERIMENTAL
Intervention: Yoga intervention (performed more than two times every week for 50-60 minutes each time after work hours)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-yoga group (did not participate in yoga)
Number of subjects: 120
Study: 23428009

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 76
Study: 20854308

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis with a duty cycle of 80%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis with a duty cycle of 70%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis with a duty cycle of 60%
Number of subjects: 0
Study: 19242403

Group type: EXPERIMENTAL
Intervention: Trazodone + clarithromycin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zolpidem + clarithromycin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zolpidem + placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Trazodone + placebo
Number of subjects: 10
Study: 16757723

Group type: EXPERIMENTAL
Intervention: Early revascularization
Number of subjects: 302

Group type: COMPARATOR
Intervention: Initial medical stabilization
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Early revascularization (hospital survivors)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Initial medical stabilization (hospital survivors)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Early revascularization (1-year survivors)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Initial medical stabilization (1-year survivors)
Number of subjects: 302
Study: 15121648

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Sertraline (both doses)
Number of subjects: 288
Study: 11698228

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Protease Inhibitors (PI group)
Number of subjects: 31
Study: 9480226

Group type: EXPERIMENTAL
Intervention: Placentas from women in the phenol polluted area (Płock)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (Kutno) placentas
Number of subjects: 226
Study: 7879746

Group type: EXPERIMENTAL
Intervention: Augmented condition (Education and Peer Support Components)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Minimal condition (Education Component)
Number of subjects: 145
Study: 3041555

Group type: EXPERIMENTAL
Intervention: Endoscopic injections of OK-432 plus systemic treatment (5-fluorouracil)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 48
Study: 30782687

Group type: EXPERIMENTAL
Intervention: LDL-C reduction to <120-160 mg/dL (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LDL-C reduction to <70 mg/dL (group B)
Number of subjects: 0
Study: 28087548

Group type: EXPERIMENTAL
Intervention: Lens extraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (laser iridotomy followed by medical therapy and glaucoma surgery)
Number of subjects: 0
Study: 26269241

Group type: EXPERIMENTAL
Intervention: Protein-based breakfast (PRO)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Carbohydrate-based breakfast (CHO)
Number of subjects: 29
Study: 23142493

Group type: EXPERIMENTAL
Intervention: Oral methylphenidate (MPH) 35 mg (approximately 0.5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: dAMPH users
Number of subjects: 16
Study: 21238643

Group type: EXPERIMENTAL
Intervention: Diaphragm pacing (DP)
Number of subjects: 6
Study: 18481293

Group type: EXPERIMENTAL
Intervention: Corticosteroids administered before biopsy
Number of subjects: 109

Group type: COMPARATOR
Intervention: No corticosteroids administered before biopsy
Number of subjects: 109
Study: 22545653

Group type: EXPERIMENTAL
Intervention: Measures of familism
Number of subjects: 5646

Group type: EXPERIMENTAL
Intervention: Measures of parental respect
Number of subjects: 5646

Group type: EXPERIMENTAL
Intervention: Measurement properties of familism and parental respect
Number of subjects: 5646
Study: 15946237

Group type: COMPARATOR
Intervention: Topical application of niacinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lectins and niacinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lectins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoglycoproteins
Number of subjects: 0
Study: 12894014

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 100

Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 100
Study: 10480514

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Fasting glucose alone
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Normal fasting glucose and postload hyperglycemia
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 1245
Study: 7766741

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg b.d. for 7 days every month plus glucomannan 2 g/day
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo two tablets b.d. for 7 days every month plus glucomannan 2 g/day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 168
Study: 2187384

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 399319

Group type: EXPERIMENTAL
Intervention: Midecacin (CM 9164)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 2
Study: 12970233

Group type: COMPARATOR
Intervention: Amiodarone (intravenous infusion for the first 24 hours at 1050 mg total, followed by oral therapy for 4 postoperative days at 4800 mg total)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Amiodarone + Atrial Septal Pacing (96 hours)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Atrial Septal Pacing (96 hours)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 29882203

Group type: EXPERIMENTAL
Intervention: Niclosamide (NCL) 1000 mg/day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Lactose (placebo) 1000 mg/day
Number of subjects: 110
Study: 27687464

Group type: EXPERIMENTAL
Intervention: Music group (listened to Vivaldi's The Four Seasons by sound-isolating headphones)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Isolation group (wore headphones but did not listen to music)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no music or sound isolation)
Number of subjects: 180
Study: 24887107

Group type: EXPERIMENTAL
Intervention: Social involvement with a wider variety of people and groups
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Support work undertaken by personal networks
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Network support
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Greater levels of illness work through networks
Number of subjects: 300
Study: 22630091

Group type: EXPERIMENTAL
Intervention: Dexamethasone (single dose perioperative intravenous steroid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No steroid (Control group)
Number of subjects: 60
Study: 20416042

Group type: EXPERIMENTAL
Intervention: TECNOB program (hospital-based intensive treatment for 1 month including diet therapy, physical training, and psychological counseling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TECNOB program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (hospital-based treatment only)
Number of subjects: 0
Study: 19102400

Group type: EXPERIMENTAL
Intervention: Somatostatin (group S)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Octreotide (group O)
Number of subjects: 50
Study: 16533939

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/d
Number of subjects: 507
Study: 12544638

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (20 g/d for 5 days, then 3 g/d for 28 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (similar amounts of glucose)
Number of subjects: 17
Study: 10840011

Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 98
Study: 8774262

Group type: EXPERIMENTAL
Intervention: Hand-warming (heated-air hand box at 55 degrees C) during hyperinsulinaemic euglycaemic clamp studies.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (box-off condition) during hyperinsulinaemic euglycaemic clamp studies.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hand-warming (2 hours) during study 2.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no hand-warming) during study 2.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hand-warming (heated-air hand box at 55 degrees C) during hyperinsulinaemia.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (box-off condition) during hyperinsulinaemia.
Number of subjects: 13
Study: 1614253

Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride 0.05%
Number of subjects: 57

Group type: COMPARATOR
Intervention: Phenylephrine hydrochloride 0.25%
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cocaine 4%
Number of subjects: 57
Study: 6394514

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (200 mg daily for the first two days, then adjusted based on symptom relief)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiapride (400 mg daily for the first two days, then adjusted based on symptom relief)
Number of subjects: 0
Study: 30833130

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care control (CON)
Number of subjects: 30
Study: 30470259

Group type: EXPERIMENTAL
Intervention: Single dose (10 mg/kg) of liposomal amphotericin B (L-AmB) given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Seven days of amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day) followed by seven days of fluconazole (1200 mg/day)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Single dose (10 mg/kg) of L-AmB
Number of subjects: 850

Group type: COMPARATOR
Intervention: Seven days of amphotericin B deoxycholate
Number of subjects: 850
Study: 27630917

Group type: EXPERIMENTAL
Intervention: Caudal route
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Transforaminal route
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Interlaminar route
Number of subjects: 140
Study: 25300392

Group type: EXPERIMENTAL
Intervention: Preventive health checks with cardiorespiratory fitness testing
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Preventive health checks without fitness testing
Number of subjects: 1500
Study: 22773591

Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Potassium chloride
Number of subjects: 30
Study: 20527050

Group type: EXPERIMENTAL
Intervention: Therapists providing high average levels of perceived Rogerian conditions
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo with clinical management
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 157
Study: 17919105

Group type: COMPARATOR
Intervention: Interleukin-2 (IL-2)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Boosts of ALVAC-HIV (vCP1433) and LIPO-6T followed by interleukin-2 (Vac-IL2 group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no immune intervention)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HIV immunizations and interleukin-2
Number of subjects: 43
Study: 16209895

Group type: EXPERIMENTAL
Intervention: I-125 seeds implantation
Number of subjects: 37
Study: 11895512

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10025892

Group type: EXPERIMENTAL
Intervention: TcRdelta and TcRgamma gene rearrangements analysis
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of two target genes (TcRgamma and TcRdelta) for monitoring minimal residual disease (MRD)
Number of subjects: 5
Study: 7572648

Group type: EXPERIMENTAL
Intervention: Anistreplase (Eminase)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 695

Group type: COMPARATOR
Intervention: Alteplase (tissue plasminogen activator)
Number of subjects: 695
Study: 2401249

Group type: EXPERIMENTAL
Intervention: ACC‐9653 (375 mg/5 ml; 232.87 mg free acid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PHT sodium (250 mg/5 ml; 229.95 mg free acid)
Number of subjects: 12
Study: 7285479

Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Post-meal state
Number of subjects: 9
Study: 30705238

Group type: EXPERIMENTAL
Intervention: Hospital deliveries of male births
Number of subjects: 75428

Group type: EXPERIMENTAL
Intervention: Second-order births conditional on the first being a girl
Number of subjects: 75428

Group type: EXPERIMENTAL
Intervention: Prenatal knowledge of the sex of the fetus
Number of subjects: 75428

Group type: COMPARATOR
Intervention: Nationally representative survey (2011 NDHS)
Number of subjects: 75428
Study: 28385131

Group type: EXPERIMENTAL
Intervention: Early ART (CD4 350‐550 cells/mm3 at ART initiation)
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Delayed ART (CD4 < 250 cells/mm3 at ART initiation or any CD4 at ART initiation)
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Both early and delayed ART
Number of subjects: 1566
Study: 27362506

Group type: EXPERIMENTAL
Intervention: 600 mg/d DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25172378

Group type: EXPERIMENTAL
Intervention: FB-30 (high saturated fatty acid meal; S/M/P ratio 5:4:1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: F-20 (control meal; S/M/P ratio 3:4:3)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: F-30 (reduced saturated fatty acid meal; S/M/P ratio 3:4:3)
Number of subjects: 11
Study: 22319064

Group type: EXPERIMENTAL
Intervention: Abciximab administered in the ambulance (ambulance group, n=127)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Abciximab administered in the catheterization laboratory (hospital group, n=129)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 256
Study: 21059575

Group type: EXPERIMENTAL
Intervention: P6 digital acupressure
Number of subjects: 53
Study: 17908370

Group type: EXPERIMENTAL
Intervention: Disease-modifying drugs (DMDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study: 15763392

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg per day for 4 weeks, then 10 mg per day for another 4 weeks)
Number of subjects: 24
Study: 12410073

Group type: EXPERIMENTAL
Intervention: Biologic secretin (2 CU/kg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Synthetic secretin (0.4 microg/kg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 10633526

Group type: EXPERIMENTAL
Intervention: Exercise training (supervised training three times a week for eight weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 8
Study: 7501382

Group type: EXPERIMENTAL
Intervention: Epley's canalith repositioning procedure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo maneuver
Number of subjects: 36
Study: 1958007

Group type: EXPERIMENTAL
Intervention: Budesonide (BU), 1200 micrograms daily, intranasally for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BE), 400 micrograms daily, intranasally for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 7044607

Group type: EXPERIMENTAL
Intervention: Surgical treatment (coronary bypass surgery)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 768
Study: 30916463

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP; n = 179)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Methadone (MET; n = 124)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Methadone treatment (for methadone-randomized individuals)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Buprenorphine treatment (for buprenorphine-randomized individuals)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Switching to buprenorphine (for methadone-randomized individuals)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Switching to methadone (for buprenorphine-randomized individuals)
Number of subjects: 303
Study: 29135073

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40